| Phase 114 trials |
|
Phase 1
|
NCT05823571 |
Jul 2023 → Mar 2028 expected |
T-cell prolymphocytic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome +2 |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04239989 |
Oct 2021 → Oct 2025 |
bronchiolitis obliterans syndrome |
M.D. Anderson Cancer Center |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT04070781 |
Jan 2020 → Dec 2021 |
graft versus host disease |
Columbia University |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03989466 |
Jan 2020 → Sep 2024 |
T-cell prolymphocytic leukemia |
M.D. Anderson Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03670069 |
Sep 2019 → Mar 2023 |
chondrosarcoma, leiomyosarcoma, myxoid liposarcoma, round cell liposarcoma +2 |
Fred Hutchinson Cancer Center |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03755414 |
Sep 2019 → Apr 2024 |
Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome |
Washington University School of Medicine |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03272464 |
May → Jul 2019 |
melanoma |
Massachusetts General Hospital |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT04358185 |
Dec 2018 → Apr 2023 |
hepatocellular carcinoma |
Imperial College London |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03497273 |
Mar 2018 → Nov 2019 |
acute graft versus host disease |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03320642 |
Feb 2018 → Feb 2021 |
hematopoietic and lymphoid cell neoplasm |
Incyte Corporation |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT02646748 |
Jan 2016 → Nov 2019 |
breast cancer, colorectal cancer, endometrial cancer, head and neck cancer +5 |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02614612 |
Dec 2015 → Jun 2016 |
acute graft versus host disease |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02559492 |
Nov 2015 → Sep 2018 |
cancer |
Incyte Corporation |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT01905813 |
Jun 2013 → Feb 2026 |
B-cell neoplasm |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
| Phase 1/29 trials |
|
Phase 1/2
|
NCT04061421 |
Nov 2021 → Aug 2027 expected |
myelodysplastic/myeloproliferative neoplasm |
Michael Savona |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04220632 |
Jun → Oct 2020 |
acute graft versus host disease |
Innovent Biologics (Suzhou) Co. Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT03978637 |
Feb 2020 → Oct 2023 |
bronchiolitis obliterans syndrome |
Incyte Corporation |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT03721965 |
Dec 2019 → Feb 2020 |
acute graft versus host disease |
Incyte Corporation |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT03697408 |
Feb 2019 → May 2024 overdue |
classic Hodgkin lymphoma |
University of Pennsylvania |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT02760485 |
Dec 2016 → Jun 2022 |
large B-cell lymphoma |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02917993 |
Dec 2016 → Dec 2025 |
lung cancer |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02018861 |
Sep 2016 → Apr 2021 |
B-cell neoplasm |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT01858883 |
Jun 2013 → Feb 2016 |
malignant pancreatic neoplasm |
Incyte Corporation |
Completed
|
No outcome recorded
|
| Phase 226 trials |
|
Phase 2
|
NCT05757219 |
May 2023 → Jun 2026 overdue |
diffuse large B-cell lymphoma |
H. Lee Moffitt Cancer Center and Research Institute |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05660421 |
Mar 2023 → Apr 2025 |
cancer, hematopoietic and lymphoid cell neoplasm |
Douglas Johnson |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT04789850 |
Feb 2023 → Feb 2026 overdue |
systemic sclerosis |
Assistance Publique - Hôpitaux de Paris |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05364762 |
Nov 2022 → Mar 2027 expected |
acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome +2 |
City of Hope Medical Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05063110 |
May 2022 → Apr 2025 |
hemophagocytic syndrome |
Assistance Publique - Hôpitaux de Paris |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04859946 |
Jan 2022 → Apr 2027 expected |
hematologic disorder |
M.D. Anderson Cancer Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04629508 |
Jul 2021 → Aug 2023 |
acquired polycythemia vera, myelofibrosis, thrombocytosis disease |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04640025 |
Mar 2021 → May 2026 |
chronic graft versus host disease, myelofibrosis, transplant-related bronchiolitis obliterans |
Incyte Corporation |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT04446182 |
Jan 2021 → Mar 2022 |
chronic graft versus host disease |
University of Utah |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT04339101 |
Nov 2020 → May 2023 |
acute leukemia, myelodysplastic syndrome, myelofibrosis, primary myelofibrosis |
City of Hope Medical Center |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04591431 |
Oct 2020 → Dec 2024 |
breast cancer, digestive system cancer, non-small cell lung carcinoma |
Fondazione per la Medicina Personalizzata |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04127721 |
Sep 2020 |
disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT04509700 |
Aug 2020 → Nov 2026 expected |
B-cell neoplasm |
Incyte Corporation |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04200365 |
Jun 2020 → Sep 2023 |
chronic graft versus host disease |
SCRI Development Innovations, LLC |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT04071366 |
Feb 2020 → Feb 2023 |
cytokine release syndrome |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03846479 |
Mar 2019 → May 2021 |
acute graft versus host disease |
John Levine |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03627052 |
Sep 2018 → Nov 2019 |
ulcerative colitis |
Incyte Corporation |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT02909569 |
Aug → Oct 2018 |
— |
Washington University School of Medicine |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT03425006 |
Jun 2018 → Jun 2021 |
non-small cell lung carcinoma |
University of Pennsylvania |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03144687 |
Jan 2018 → Mar 2020 |
myeloproliferative neoplasm |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02456675 |
Jun 2015 → Dec 2016 |
Hodgkins lymphoma |
Incyte Corporation |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT02355431 |
Dec 2014 → Sep 2015 |
hematopoietic and lymphoid cell neoplasm, non-small cell lung carcinoma |
Incyte Corporation |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT02257619 |
Sep 2014 → Feb 2016 |
non-small cell lung carcinoma |
Incyte Corporation |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01633372 |
Jul 2012 → Dec 2013 |
myeloproliferative neoplasm |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01634087 |
Jun 2012 → Jan 2013 |
psoriasis |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01626573 |
Mar 2012 → Jul 2013 |
rheumatoid arthritis |
Incyte Corporation |
Completed
|
No outcome recorded
|
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT03584516 |
Jan 2019 → Nov 2023 |
chronic graft versus host disease |
Incyte Corporation |
Terminated
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT03139604 |
Jul 2017 → May 2019 |
acute graft versus host disease |
Incyte Corporation |
Completed
|
No outcome recorded
|
| Phase not stated2 trials |
| — |
NCT05561985 |
— |
— |
Incyte Corporation |
Available
|
No outcome recorded
|
| — |
NCT03906318 |
— |
aplastic anemia |
Incyte Corporation |
No longer available
|
No outcome recorded
|